WO2021070934A1 - がんの検査方法 - Google Patents

がんの検査方法 Download PDF

Info

Publication number
WO2021070934A1
WO2021070934A1 PCT/JP2020/038300 JP2020038300W WO2021070934A1 WO 2021070934 A1 WO2021070934 A1 WO 2021070934A1 JP 2020038300 W JP2020038300 W JP 2020038300W WO 2021070934 A1 WO2021070934 A1 WO 2021070934A1
Authority
WO
WIPO (PCT)
Prior art keywords
molecule
bc2lcn
cancer
gal3bp
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/038300
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
浩章 舘野
小田 竜也
治 下村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology
University of Tsukuba
Original Assignee
National Institute of Advanced Industrial Science and Technology
University of Tsukuba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Advanced Industrial Science and Technology, University of Tsukuba filed Critical National Institute of Advanced Industrial Science and Technology
Priority to EP20873535.7A priority Critical patent/EP4043881A4/en
Priority to KR1020227012018A priority patent/KR102896955B1/ko
Priority to CN202080071169.XA priority patent/CN114556101B/zh
Priority to JP2021551720A priority patent/JP7656829B2/ja
Publication of WO2021070934A1 publication Critical patent/WO2021070934A1/ja
Priority to US17/717,764 priority patent/US12618842B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/548—Carbohydrates, e.g. dextran
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Definitions

  • the present invention relates to a cancer test method and a test kit for that purpose.
  • BC2LCN is a glycoprotein, a type of lectin, and has previously reported affinity for glycoprotein sugar chains H-type1 (Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc) and H-type3 (Fuc ⁇ 1-2Gal ⁇ 1-3GalNAc). It has been clarified that it can be used as a probe for detecting an undifferentiated marker of human ES cells and iPS cells expressing podocalyxin having a property and having an H-type3 sugar chain (Patent Document 1). Further, according to a previous report, it has been clarified that BC2LCN strongly binds to cancer tissues and can be used as a cancer marker detection probe (Patent Document 2).
  • Patent Document 2 a sandwich assay of BC2LCN and an antibody that binds to keratan sulfate has confirmed the presence of a protein recognized by BC2LCN and keratan sulfate in the blood components of some cancer patients.
  • Serpin A3 is also called ⁇ 1-antichymotrypsin and is known to be associated with diseases such as some tumors. Serpin A3 has been developed as a blood test marker (Non-Patent Document 1).
  • Gal3BP also called LGAL3SBP or MAC-2-BP
  • LGAL3SBP MAC-2-BP
  • the present invention relates to a cancer test method and a test kit for that purpose.
  • a method of analyzing a blood sample obtained from a subject Blood samples by sandwich assay or immunochromatography assay performed with a first molecule selected from the group consisting of antibodies that bind BC2LCN, Serpin A3, and antibodies that bind Gal3BP, and a second molecule that is BC2LCN.
  • a method comprising analyzing the blood components contained therein.
  • a kit for sandwich assays or immunochromatography assays that can be used to measure the amount of glycoprotein in a blood sample of interest.
  • (11) Labeled selected from the group consisting of a second molecule that is immobilized BC2LCN, labeled BC2LCN, an antibody that binds to labeled Serpin A3, and an antibody that binds to labeled Gal3BP.
  • the kit according to (12) above, wherein the cancer is a cancer selected from the group consisting of pancreatic cancer and colon cancer.
  • the kit according to (13) above, wherein the cancer is stage 1 or 2 pancreatic cancer.
  • a method for predicting whether or not a subject has cancer which comprises carrying out the method according to any one of (1) to (7) above.
  • (1A) A method for analyzing a biological sample obtained from a subject. It is carried out using a first molecule selected from the group consisting of a molecule that binds to a BC2LCN-binding sugar chain, a molecule that binds to SerpinA3, and a molecule that binds to Gal3BP, and a second molecule that is BC2LCN.
  • a method comprising analyzing components contained in a biological sample by an assay.
  • (2A) The method according to (1A) above, wherein the first molecule is an antibody that binds to Serpin A3.
  • (3A) The method according to (1A) above, wherein the first molecule is an antibody that binds to Gal3BP.
  • (4A) The method according to (1A) above, wherein the first molecule is BC2LCN.
  • (5A) The method according to any one of (1A) to (4A) above, wherein the subject has or has the possibility of cancer.
  • (6A) The method according to (5A) above, wherein the subject has or has the possibility of pancreatic cancer.
  • (7A) The method of (6A) above, wherein the subject has or is likely to have stage 1 or 2 pancreatic cancer.
  • (8A) A first molecule selected from the group consisting of a molecule that binds to BC2LCN, SerpinA3, and a molecule that binds to Gal3BP, and a second molecule that is a molecule that binds to a BC2LCN-binding sugar chain.
  • kits for sandwich assay a kit for immunochromatography assay, a kit for lectin electrophoresis, and mass, which can measure the amount of glycoprotein in a biological sample of interest using a first molecule and a second molecule.
  • Kits for analysis kits for lectin affinity chromatography or kits for ⁇ TAS.
  • 10A The kit according to (8A) above, wherein the first molecule is an antibody that binds to Gal3BP, and the protein portion of the glycoprotein is Gal3BP.
  • (11A) Labeled selected from the group consisting of a second molecule that is immobilized BC2LCN and a labeled BC2LCN, an antibody that binds to labeled Serpin A3, and an antibody that binds to labeled Gal3BP.
  • the kit according to (8A) above which comprises a first molecule.
  • (12A) The kit according to any one of (8A) to (11A) above, which is used for detecting cancer.
  • (13A) The kit according to (12A) above, wherein the cancer is pancreatic cancer.
  • (14A) The kit according to (13A) above, wherein the cancer is stage 1 or 2 pancreatic cancer.
  • FIG. 1 shows the results of a sandwich assay in which the concentrations of blood factors that can be simultaneously recognized by two molecules of BC2LCN were measured in blood samples of patients with various cancers and healthy subjects.
  • FIG. 2 shows the results of precipitating blood components that bind to BC2LCN using BC2LCN from a blood sample, and then performing gel electrophoresis and Western blotting using BC2LCN (left) and silver staining (right). ..
  • FIG. 3 shows the results of Western blotting of blood components that bind to BC2LCN from a blood sample using BC2LCN, which were then subjected to gel electrophoresis and then antibody against Seprin A3 (left) and antibody against Gal3BP (right), respectively. Shown.
  • FIG. 1 shows the results of a sandwich assay in which the concentrations of blood factors that can be simultaneously recognized by two molecules of BC2LCN were measured in blood samples of patients with various cancers and healthy subjects.
  • FIG. 2 shows the results of precipitating blood components that bind to BC
  • FIG. 4 shows the results of a sandwich assay using an antibody that binds BC2LCN and SerpinA3 in blood samples of patients with various cancers and healthy subjects.
  • FIG. 5 shows the results of a sandwich assay using an antibody that binds to BC2LCN and Gal3BP in blood samples of patients with various cancers and healthy subjects.
  • FIG. 6 shows the concentration of blood factors that can be simultaneously recognized by two molecules of BC2LCN, the concentration of BC2LCN-binding SerpinA3, the concentration of BC2LCN-binding Gal3BP, and two types of blood samples of pancreatic cancer patients and healthy subjects. The results of the concentration of Serpin A3 measured using different anti-Serpin A3 antibodies are shown.
  • FIG. 7 shows the concentration of blood factors that can be simultaneously recognized by two molecules of BC2LCN, the concentration of BC2LCN-binding SerpinA3, the concentration of BC2LCN-binding Gal3BP, and two types of blood samples of pancreatic cancer patients and healthy subjects.
  • FIG. 5 is an ROC curve showing the relationship between sensitivity and specificity in an evaluation system for detecting pancreatic cancer using the concentration of Serpin A3 measured using different anti-Serpin A3 antibodies as an index.
  • FIG. 8A shows the results of measuring the concentrations of blood factors that can be simultaneously recognized by two molecules of BC2LCN in a blood sample of a pancreatic cancer patient for each stage in the UICC TMN classification.
  • FIG. 8B shows the results of measuring the concentration of BC2LCN-binding Serpin A3 in a blood sample of a pancreatic cancer patient for each stage in the UICC TMN classification.
  • FIG. 8C shows the results of measuring the concentration of BC2LCN-binding Gal3BP in a blood sample of a pancreatic cancer patient for each stage in the UICC TMN classification.
  • FIG. 8D shows the results of measuring the concentration of Serpin A3 in a blood sample of a pancreatic cancer patient measured using two different anti-Serpin A3 antibodies for each stage in the UICC TMN classification.
  • FIG. 9 shows histological staining of normal and pancreatic tissue sections containing pancreatic cancer with rBC2LCN (sometimes referred to simply as “rBC2” in the figure), and immunohistochemistry against Serpin A3 and Gal3BP. The results of academic staining are shown.
  • FIG. 10 shows a sandwich assay using two molecules of BC2LCN, a sandwich assay using BC2LCN and an anti-Serpin A3 antibody, a sandwich assay using BC2LCN and an anti-Gal3BP antibody, an ELISA using an anti-Serpin A3 antibody, and an anti-Gal3BP antibody.
  • FIG. 10 shows a sandwich assay using two molecules of BC2LCN, a sandwich assay using BC2LCN and an anti-Serpin A3 antibody, a sandwich assay using BC2LCN and an anti-Gal3BP antibody, an ELISA using an anti-Serpin A3 antibody, and an anti-Gal3BP antibody.
  • FIG. 10 shows a sandwich as
  • FIG. 11 shows a sandwich assay using two molecules of BC2LCN, a sandwich assay using BC2LCN and an anti-Serpin A3 antibody, a sandwich assay using BC2LCN and an anti-Gal3BP antibody, an ELISA using an anti-Serpin A3 antibody, and an anti-Gal3BP antibody.
  • the ROC curve for detecting pancreatic cancer patients in healthy subjects and patients with chronic pancreatitis in the ELISA system is shown. The analysis was performed using blood samples.
  • FIG. 12 shows a sandwich assay using two molecules of BC2LCN, a sandwich assay using BC2LCN and an anti-Serpin A3 antibody, a sandwich assay using BC2LCN and an anti-Gal3BP antibody, an ELISA using an anti-Serpin A3 antibody, and an anti-Gal3BP antibody.
  • the ROC curve for detecting a stage I pancreatic cancer patient in a healthy subject in the ELISA system is shown. The analysis was performed using blood samples.
  • FIG. 13 shows a sandwich assay using two molecules of BC2LCN, a sandwich assay using BC2LCN and an anti-Serpin A3 antibody, a sandwich assay using BC2LCN and an anti-Gal3BP antibody, an ELISA using an anti-Serpin A3 antibody, and an anti-Gal3BP antibody.
  • the ROC curve for detecting stage II pancreatic cancer patients in a healthy subject in the ELISA system is shown. The analysis was performed using blood samples.
  • FIG. 14 shows stage III pancreatic cancer in a healthy subject in a sandwich assay with two molecules of BC2LCN, a sandwich assay with BC2LCN and an anti-Serpin A3 antibody, and a sandwich assay with BC2LCN and an anti-Gal3BP antibody.
  • FIG. 15 shows stage IV pancreatic cancer in a healthy subject in a sandwich assay with two molecules of BC2LCN, a sandwich assay with BC2LCN and an anti-Serpin A3 antibody, and a sandwich assay with BC2LCN and an anti-Gal3BP antibody.
  • the ROC curve for detecting a patient is shown. The analysis was performed using blood samples.
  • FIG. 16 shows blood samples of patients before, 30 days after, and 3 months (3 m) after surgery to remove pancreatic cancer, analyzed by sandwich assay using BC2LCN and anti-Serpin A3 antibody. The result is shown.
  • FIG. 16 shows blood samples of patients before, 30 days after, and 3 months (3 m) after surgery to remove pancreatic cancer, analyzed by sandwich assay using BC2LCN and anti-Serpin A3 antibody. The result is shown.
  • FIG. 17 shows blood samples of patients before, 30 days after, and 3 months (3 m) after surgery to remove pancreatic cancer, analyzed by a sandwich assay using BC2LCN and anti-Gal3BP antibody. The result is shown.
  • FIG. 18 shows the results of analysis of blood samples of patients before, 30 days after the surgery (30 POD), and 3 months after the surgery (3 m) by ELISAA using CA19-9. Shown.
  • FIG. 19 shows a patient (patient A) before, 1 day after the surgery (1 POD), 7 days after the surgery (7 POD), and 30 days after the surgery (30 POD), and after recurrence. The results of analysis of blood samples in a sandwich assay using BC2LCN and anti-Serpin A3 antibody are shown.
  • the term "subject” means mammals, especially mammals including humans.
  • a “subject” can be a healthy person, a patient with cancer, or a patient with the potential to have cancer.
  • tumor means a cell population that exhibits self-sustaining growth. Independent proliferation means the property of cells that escape the normal control of cell proliferation in the body and continue to proliferate autonomously. Tumors are roughly classified into benign tumors and malignant tumors (cancers). Benign tumors are tumors that grow autonomously but do not metastasize, infiltrate, or cause cachexia. In addition to autonomous growth, malignant tumors cause one or more of infiltration, metastasis, and cachexia into normal tissue.
  • biological sample means a sample obtained from a subject (eg, tissue, cells, extracellular fluid, and body fluid).
  • Body fluids include blood, urine, ascites, pleural effusion, and secretions (eg, endocrine and exocrine fluids, such as digestive juices such as pancreatic juice).
  • a "blood sample” is blood obtained from a subject (eg, peripheral blood) or a sample derived from blood (eg, serum and plasma).
  • the "blood component” is a component contained in blood, particularly a liquid component contained in blood. In the present specification, when the biological sample is a blood sample, the component is a blood component, as will be described later.
  • antibody means immunoglobulin.
  • An antibody is a biomolecule that has the property of binding to an antigen.
  • Antibodies can have specificity for the antigen.
  • the antibody may be a monoclonal antibody or a polyclonal antibody.
  • Antibodies can include bispecific antibodies.
  • the antibody can be a full-length antibody and a fragment thereof that has binding to the antigen.
  • BC2LCN is the N-terminal domain of BC2LC, which is a lectin derived from Burkholderia cenocepacia (Sulak, O., et al., Structure, 18 (1): 59-72, 2010). .. According to previous reports, BC2LCN has been shown to have an affinity for glycoprotein sugar chains H-type1 (Fuc ⁇ 1-2Gal ⁇ 1-3GlcNAc) and H-type3 (Fuc ⁇ 1-2Gal ⁇ 1-3GalNAc), and It has been clarified that BC2LCN can be used as an undifferentiated marker of human ES cells and iPS cells expressing podocalyxin having an H-type3 sugar chain (WO2014 / 1236146).
  • BC2LCN is specifically expressed in cancer tissues and can be used to detect cancer (WO2017 / 061449).
  • a sandwich assay of BC2LCN and an antibody that binds to keratan sulfate confirms the presence of a protein recognized by BC2LCN and keratan sulfate in the blood components of some cancer patients.
  • BC2LCN produced using a host other than cenocepacia may be referred to as recombinant BC2LCN or rBC2LCN.
  • BC2LCN-binding sugar chain or protein a sugar chain or protein to which BC2LCN binds
  • BC2LCN-binding proteins are modified with BC2LCN-binding sugar chains.
  • the BC2LCN-binding sugar chain can be an H-type1 sugar chain and / or an H-type3 sugar chain.
  • BC2LCN includes, for example, lectins registered as YP_002232818 at the National Center for Biotechnology Information (NCBI).
  • NCBI National Center for Biotechnology Information
  • BC2LCN it can be used as long as it has a binding ability to a sugar chain, but as BC2LCN, one having a modified (for example, improved) binding ability to a sugar chain as disclosed in JP2020-146027 can also be used.
  • BC2LCN a protein having an amino acid sequence of 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more or 100% identical to the amino acid sequence of the lectin registered as YP_002232818 (BC2LCN). Can be mentioned. BC2LCN binds to at least one selected from the group consisting of H-type3 sugar chains and H-type1 sugar chains.
  • Serpin A3 is a serine protease inhibitor (serpin) also known as ⁇ 1 antichymotrypsin (AACT).
  • serpin serine protease inhibitor
  • AACT ⁇ 1 antichymotrypsin
  • the Serpin A3 protein can be produced by cleaving a signal peptide consisting of the 1st to 23rd amino acid sequences from a 423 amino acid long precursor (eg, NCBI reference number: NP_001076.2).
  • Gal3BP is a galectin-3-binding protein.
  • Gal3BP can be a protein obtained by translating from mRNA having a base sequence registered as National Center for Biotechnology Information (NCBI) reference number NM_0055677.4.
  • NCBI National Center for Biotechnology Information
  • the Gal3BP protein is cleaved, for example, from a 585 amino acid long precursor (eg, having an amino acid sequence registered as NCBI reference number: NP_005558.1) with a signal peptide consisting of the 1st to 18th amino acid sequences. Can occur.
  • Gal3BP has a molecular weight of 90 kDa in serum and is found in high concentrations in the serum of patients with breast cancer, lung cancer, rectal colon cancer, ovarian cancer, and endometrial cancer (Koths, K. etal., J. Biol. Chem. 268: 14245-14249, 1993).
  • the "sandwich assay” is an assay used to detect a target component contained in a sample. Sandwich assays can be performed by one of ordinary skill in the art.
  • the target component is typically contacted with a capture molecule A that binds to the target component immobilized on a support (eg, substrate and beads) to capture the target component on the support and then.
  • the capture molecule B that binds to the labeled target component is brought into contact with the target component, and the target component captured on the support is detected using the label as an index. It is an assay.
  • any support used in ordinary immunological measurement methods can be used, and for example, polystyrene, polyacrylic acid, etc.
  • Organic substances such as acid copolymers; inorganic substances such as glass, silicon oxide, silica, porous glass, suri glass, alumina, silica gel, metal oxides; magnetic substances such as iron, cobalt, nickel, magnetite, chromate, etc.; and these.
  • Examples thereof include those prepared using the above magnetic alloy as a material. Immobilization can be done on a solid phase (eg, any surface such as beads, magnetic beads, membranes, plates, etc.). As the magnetic beads, various commercially available ones can be used. As the magnetic beads, for example, the beads disclosed in WO2012 / 173002A may be used. In a sandwich assay, the captive molecule A to be immobilized and the captive molecule B labeled are usually required to bind to the target component at the same time without competing with each other for binding to the target component.
  • the capture molecule A can be the first molecule described below and the capture molecule B can be the second molecule.
  • the capture molecule A can be the second molecule described below, and the capture molecule B can be the first molecule.
  • the sandwich assay can also be performed with a microfluidic chip (micro-total analysis systems; ⁇ TAS).
  • the microfluidic chip comprises a flow path, the flow path having a sample inlet, for example, at the sample inlet, the capture molecule X to which a polycation or polyanion (eg, DNA) is bound and the sample are brought into contact with each other for capture.
  • a polycation or polyanion eg, DNA
  • a complex of the molecule X and the target component is formed, an electric field is applied to move the complex, and when the labeled capture molecule Y existing in the middle of the flow path and the complex come into contact with each other, the target component and the target component X
  • a complex of trapping molecules Y is formed, and the electric field allows the complex to travel through the flow path and reach the detection section on the flow path, where it can be detected by a label bound to the trapping molecule Y.
  • the detection can be carried out optically, for example, by a laser or the like.
  • the capture molecule X can be the first molecule described below and the capture molecule Y can be the second molecule.
  • the capture molecule X can be the second molecule described below, and the capture molecule Y can be the first molecule.
  • the presence of multiple biomarkers can also be detected in parallel using ⁇ TAS.
  • the supplementary molecule N and the supplementary molecule M are immobilized on separate beads A and B, respectively, and when the target molecule is present, the target molecule, the supplementary molecule N and the beads A, and the supplementary molecule M and the beads are present.
  • a complex is formed by irradiating a bead A containing a photosensitizer containing a photosensitizer that forms a complex with B and releases single-term oxygen by excitation to form a complex (beads A and B are in close proximity to each other).
  • an assay eg, AlphaLISA
  • an assay that detects the presence of a target molecule by detecting the light from the bead B so that the monomorphic oxygen reaches the bead B only (when it is), thereby causing the bead B to chemiluminescent.
  • the present invention may provide an AlphaLISA assay kit comprising beads on which BC2LCN is immobilized and beads on which an antibody that binds Serpin A3 or Gal3BP is immobilized.
  • FRET fluorescence resonance energy transfer
  • BRET bioluminescence resonance energy transfer
  • Etc. can also be used to detect the presence of the target molecule.
  • beads or supports for immobilization are not required.
  • the present invention may provide kits for such assays.
  • the "immunochromatometric assay” is an assay used to detect a target component contained in a sample, and is usually contained in a capture molecule C labeled with a label such as gold colloid and a liquid sample.
  • the target component is contacted to form a complex of the label-capturing molecule C and the target component, and then the complex is transferred onto the chromatomembrane and brought into contact with the supplementary molecule D immobilized on the test line.
  • An assay in which a complex of a label capture molecule C and a target component is captured on a test line and the label on the test line is detected as an index.
  • the labeled capture molecule C and the capture molecule D immobilized on the test line do not usually compete with each other for binding to the target component and must bind to the target component at the same time.
  • a control line is provided in addition to the test line, and the control line contains a molecule that binds to the capture molecule C (an antibody or the like, and if the capture molecule C is an IgG antibody, it can be an anti-IgG antibody). It is possible to capture the label-capturing component C that has been immobilized and has not bound to the target component.
  • a sample pad containing the sample containing the sample, a conjugate pad in which the labeled capture molecule C is present, a membrane which is a moving layer to which the complex of the target component and the capture molecule C in the sample moves, and a membrane in the sample.
  • a strip containing an absorption pad that absorbs water is provided in this order, and on the membrane there is a test line on which the capture molecule D is immobilized and a control line in which the antibody against the capture molecule C is immobilized. ..
  • the labeled capture molecule C and the target component form a complex, and the complex is captured by the capture molecule D immobilized on the test line and also captured by the control line. .. If the sample does not contain the component of interest, the sample moves towards the absorption pad and the labeled capture molecule C does not form a complex, is not captured on the test line, but is captured only on the control line. It will be. As a result, if the control line develops color and the test line develops color, it indicates that the sample contains the target component, and if the control line develops color and the test line does not develop color, the sample contains the target component. Is shown not to be included.
  • the capture molecule C can be the first molecule described below and the capture molecule D can be the second molecule.
  • the capture molecule C can be the second molecule described below, and the capture molecule D can be the first molecule.
  • lectin electrophoresis is electrophoresis using a gel containing a lectin, which means that molecules that interact with lectins during electrophoresis have a slower migration rate than molecules that do not interact with each other. This is a method for separating lectin-binding molecules.
  • the lectin is either free in the gel or immobilized on the gel. Since lectins hardly move by electrophoresis, the migration rate of glycoproteins can be reduced by simply mixing with the gel material to prepare a gel. Alternatively, the lectin is non-covalently or covalently linked to the gel.
  • the biological sample can be separated by lectin electrophoresis using BC2LCN as the lectin.
  • Molecules with BC2LCN-binding sugar chains repeatedly interact with lectins immobilized on the gel during electrophoresis, which delays electrophoresis.
  • BC2LCN non-bonding molecules do not interact with lectins immobilized on the gel and migrate quickly.
  • Lectin electrophoresis can be appropriately carried out by those skilled in the art.
  • lectin affinity chromatography is chromatography utilizing the fact that lectins have a property of specifically binding to a sugar chain.
  • affinity chromatography for example, affinity chromatography is performed on a sample using a column containing an insoluble support on which a lectin is immobilized. If a component in the sample has an affinity for lectins, the component will be separated from the other components.
  • BC2LCN can be used as the lectin.
  • a blood component capable of simultaneously binding two BC2LCNs was found in a sandwich assay using immobilized BC2LCN and labeled BC2LCN. It has been found that it is present and that the serum content of the blood component in patients with cancer tends to be higher than in healthy individuals.
  • BC2LCN-binding SerpinA3 was present as a blood component in a sandwich assay using BC2LCN and an antibody that binds to SerpinA3, and We have found that the serum levels of BC2LCN-binding Serpin A3 in patients with cancer tend to be higher than in healthy individuals.
  • BC2LCN-binding Gal3BP was present as a blood component in a sandwich assay using BC2LCN and an antibody that binds to Gal3BP.
  • serum levels of BC2LCN-binding Gal3BP in patients with cancer tend to be higher than in healthy individuals.
  • a method of analyzing a biological sample obtained from a subject One or more components (sometimes referred to as "target components") selected from the group consisting of Serpin A3 (eg, BC2LCN-binding Serpin A3) and Gal3BP (eg, BC2LCN-binding Gal3BP) in a biological sample obtained from a subject. ), Including The method is provided.
  • the method of the present invention may include preparing a biological sample.
  • the method of the present invention may further include measuring the amount of the above components.
  • one or more components selected from the group consisting of Serpin A3 (for example, BC2LCN-binding Serpin A3) and Gal3BP (for example, BC2LCN-binding Gal3BP) are detected using a molecule that binds to the component. can do.
  • the one or more components can be separated from the other components before the one or more components can be detected.
  • SerpinA3 can be detected using a molecule that binds to SerpinA3. Two different molecules that can simultaneously bind to Serpin A3 can also be used. Using two different molecules that can bind to SerpinA3 at the same time, SerpinA3 can be detected by immunochromatography and sandwich assays.
  • Serpin A3 can also be detected by mass spectrometry. In either case, a calibration curve can be obtained using the standard substance of Serpin A3. Further, the measured value for SerpinA3 can be applied to the obtained verification line to quantify SerpinA3. Further, BC2LCN-binding SerpinA3 can be detected by using a molecule that binds to a BC2LCN-binding sugar chain and a molecule that binds to SerpinA3. The molecule that binds to the BC2LCN-binding sugar chain may include separating the BC2LCN-binding molecule from the others by using the molecule that binds to the BC2LCN-binding sugar chain, or the BC2LCN-binding molecule.
  • the molecule bound to the sugar chain may include separating the BC2LCN-binding molecule from the others by using lectin affinity chromatography or lectin electrophoresis. It may also include separating Serpin A3 from other components. Either of the separation of Serpin A3 and the separation of the BC2LCN-binding component may be carried out first.
  • Gal3BP can be detected using a molecule that binds to Gal3BP. Two different molecules that can simultaneously bind to Gal3BP can also be used. Using two different molecules that can simultaneously bind to Gal3BP, Gal3BP can be detected by immunochromatography and sandwich assays. Gal3BP can also be detected by mass spectrometry.
  • a calibration curve can be obtained using the standard substance of Gal3BP.
  • Gal3BP can be quantified by applying the measured value for Gal3BP to the obtained verification line.
  • BC2LCN-binding Gal3BP can be detected by using a molecule that binds to a BC2LCN-binding sugar chain and a molecule that binds to Gal3BP.
  • the molecule that binds to the BC2LCN-binding sugar chain may include separating the BC2LCN-binding molecule from the others by using the molecule that binds to the BC2LCN-binding sugar chain, or the BC2LCN-binding molecule.
  • the molecule bound to the sugar chain may include separating the BC2LCN-binding molecule from the others by using lectin electrophoresis. It may also include separating Gal3BP from other components. Either Gal3BP separation or BC2LCN-binding component separation may be performed first.
  • a method of analyzing a biological sample obtained from a subject It is carried out using a first molecule selected from the group consisting of a molecule that binds to a BC2LCN-binding sugar chain, a molecule that binds to SerpinA3, and a molecule that binds to Gal3BP, and a second molecule that is BC2LCN.
  • the assay provides a method comprising analyzing a component (sometimes referred to as a "target component") contained in a biological sample.
  • the biological sample is a biological sample obtained from the above-mentioned subject.
  • the subject can be a subject who has or may have cancer.
  • the cancer can be, for example, pancreatic cancer.
  • Pancreatic cancer can be, for example, stage pancreatic cancer selected from the group consisting of stages I, II, III, and IV, eg, stage I pancreatic cancer, eg, stage II pancreatic cancer. possible.
  • Biological samples include, for example, tissues, cells, and body fluids. Body fluids include blood (eg, plasma and serum), sweat, saliva, urine, ascites, pleural effusion, and secretions (eg, endocrine and exocrine fluids, eg, digestive juices such as pancreatic fluid).
  • Tissues and cells can be, for example, cancer or suspected cancer, respectively. Each tissue and cell contains, for example, cancer or a suspected cancer.
  • Examples of the molecule that binds to the BC2LCN-binding sugar chain include an antibody that binds to the BC2LCN-binding sugar chain or an antigen-binding fragment thereof. Molecules that bind to BC2LCN-binding sugar chains also include aptamers that bind to BC2LCN-binding sugar chains (eg, nucleic acid aptamers selected from the group consisting of DNA and RNA). Further, examples of the molecule that binds to the BC2LCN-binding sugar chain include a medium molecule such as a cyclic peptide. Molecules that bind to these BC2LCN-binding sugar chains can be obtained by methods well known to those skilled in the art.
  • an antibody that binds to a BC2LCN-binding sugar chain can be obtained from a non-human mammal immunized with the BC2LCN-binding sugar chain.
  • Aptamers that bind to BC2LCN-binding sugar chains can be obtained from the nucleic acid pool by utilizing the affinity for BC2LCN-binding sugar chains.
  • the cyclic peptide that binds to the BC2LCN-binding sugar chain can be obtained from the cyclic peptide pool by utilizing the affinity for the BC2LCN-binding sugar chain.
  • the molecule that binds to the BC2LCN-binding sugar chain can be, for example, BC2LCN.
  • Examples of the molecule that binds to SerpinA3 include an antibody that binds to SerpinA3 or an antigen-binding fragment thereof. Molecules that bind to SerpinA3 also include aptamers that bind to SerpinA3 (eg, nucleic acid aptamers selected from the group consisting of DNA and RNA). Further, examples of the molecule that binds to Serpin A3 include a medium molecule such as a cyclic peptide. Molecules that bind to Serpin A3 can be obtained by methods well known to those skilled in the art. For example, an antibody that binds to Serpin A3 can be obtained from a non-human mammal immunized with Serpin A3.
  • Aptamers that bind to Serpin A3 can be obtained from the nucleic acid pool by utilizing their affinity for Serpin A3.
  • the cyclic peptide that binds to Serpin A3 can be obtained from the cyclic peptide pool by utilizing its affinity for Serpin A3.
  • Serpin A3 may form a complex with other components in a biological sample. In the present invention, such a complex may be detected.
  • PSA is another component that forms a complex with Serpin A3. Therefore, SerpinA3 can also be detected using a molecule that binds to PSA and a molecule that binds to SerpinA3.
  • labeled recombinant PSA can be used to detect SerpinA3 by taking advantage of the binding property of SerpinA3 to PSA.
  • Examples of the molecule that binds to Gal3BP include an antibody that binds to Gal3BP or an antigen-binding fragment thereof. Molecules that bind to Gal3BP also include aptamers that bind to Gal3BP (eg, nucleic acid aptamers selected from the group consisting of DNA and RNA). Further, examples of the molecule that binds to Gal3BP include a medium molecule such as a cyclic peptide. Molecules that bind to these Gal3BPs can be obtained by methods well known to those skilled in the art. For example, an antibody that binds to Gal3BP can be obtained from a non-human mammal immunized with Gal3BP.
  • Aptamers that bind to Gal3BP can be obtained from the nucleic acid pool using their affinity for Gal3BP.
  • the cyclic peptide that binds to Gal3BP can be obtained from the cyclic peptide pool by utilizing the affinity for Gal3BP.
  • Gal3BP may form a complex with other components in a biological sample. In the present invention, such a complex may be detected.
  • other components that form a complex with Gal3BP include galectin (particularly galectin-3). Therefore, Gal3BP can also be detected using a molecule that binds to galectin (particularly galectin 3) and a molecule that binds to Gal3BP.
  • labeled recombinant galectin (particularly galectin 3) can be used to detect Gal3BP by taking advantage of the binding property of Gal3BP to galectin (particularly galectin 3).
  • a biological sample for example, a blood sample obtained from a subject.
  • the component eg, blood component
  • a component (sometimes referred to as a target component (eg, a target blood component)) selected from the group consisting of a component, Serpin A3 (eg, BC2LCN-binding Serpin A3), and Gal3BP (eg, BC2LCN-binding Gal3BP).
  • Serpin A3 eg, BC2LCN-binding Serpin A3
  • Gal3BP eg, BC2LCN-binding Gal3BP
  • the subject when one, two or all of the above components are detected, it indicates that the subject may be cancer.
  • the concentration of one of the above components when the concentration of one of the above components is larger than the cutoff value, it indicates that the subject may be cancer.
  • the subject can be a human, for example, a healthy person, a patient with cancer, and a patient who has the possibility of having cancer.
  • the cancers are pancreatic cancer, colon cancer, rectal adenocarcinoma, bladder cancer, breast cancer, non-small cell lung cancer, gastric cancer, cervical cancer, uterine body cancer, hepatocellular carcinoma, It can be one or more cancers selected from the group consisting of thyroid cancer, prostate cancer, melanoma, esophageal cancer, ovarian cancer, bile duct cancer, non-hodgkin lymphoma, and chronic myeloid leukemia.
  • the cancer can be pancreatic cancer.
  • the pancreatic cancer can be a stage pancreatic cancer selected from the group consisting of stages I and II.
  • the pancreatic cancer can be stage I.
  • the pancreatic cancer can be stage II.
  • the target component or target blood component is a component capable of simultaneously binding two BC2LCNs.
  • the target component or target blood component is BC2LCN-binding Serpin A3.
  • the target component or target blood component is BC2LCN-binding Gal3BP.
  • the cancer can be as described above, such as pancreatic cancer, colon cancer, rectal adenocarcinoma, bladder cancer, breast cancer, uterine body cancer, hepatocellular carcinoma, thyroid cancer.
  • the cancer can be pancreatic cancer.
  • the pancreatic cancer can be a stage pancreatic cancer selected from the group consisting of stages I and II. In some embodiments, the pancreatic cancer can be stage I. In some embodiments, the pancreatic cancer can be stage II.
  • the cutoff value is, for example, 0, the 1st quartile, the mean, the 3rd quartile, or the maximum, or the concentration of the target component (eg, the target blood component) of the healthy subject group. It can be a value between any two of these (eg, the third quartile or the maximum value or a value in between). In some embodiments, the cutoff value is, for example, 0, the first quartile, average, third quartile, or maximum of the target component (eg, target blood component) concentration of the cancer patient group. Or it can be a value between any two of these.
  • the cutoff value is a cutoff value at the point closest to the points of sensitivity 1 and specificity 1 on the ROC curve, a value greater than the cutoff value, or a value less than the cutoff value. Can be. In some embodiments, the cutoff value can also be a cutoff value at the point where the Youden Index is maximal, a value greater than the cutoff value, or a value smaller than the cutoff value.
  • the cutoff value can be determined by the balance between sensitivity and false positive rate.
  • the cutoff value can be set low if you want to detect as many cancer patients as possible even if there are many false positives (if you want to increase the sensitivity), and you want to reduce the false positives (instead, even if the sensitivity decreases). If it is good), it can be set high, and a person skilled in the art can set it appropriately according to the purpose of the inspection.
  • the concentration of the target component (for example, the target blood component) in the biological sample (for example, blood sample) obtained from the subject is larger than the cutoff value
  • the subject is cancerous. You can get information that you may have. Therefore, in the analysis method of the present invention, when the concentration of the target component (for example, the target blood component) in the biological sample (for example, blood sample) obtained from the target is larger than the cutoff value, the target is. May include providing information indicating that the patient may have cancer.
  • the subject when the concentration of the target component (for example, the target blood component) in the biological sample (for example, blood sample) obtained from the subject is larger than the cutoff value, the subject is pancreatic cancer. You can get information that you may have pancreatic cancer. Therefore, in the analysis method of the present invention, when the concentration of the target component (for example, the target blood component) in the biological sample (for example, blood sample) obtained from the subject is larger than the cutoff value, the subject is pancreatic. It may include providing information indicating that you may have cancer.
  • a target component for example, a target blood component
  • a biological sample for example, a blood sample
  • a biological sample for example, a blood sample
  • the concentration of the target component (for example, the target blood component) in the biological sample (for example, blood sample) obtained from the target is larger than the cutoff value
  • the target is early. It may include providing information indicating that you may have cancer.
  • Early cancer can be early pancreatic cancer.
  • the stage classification of pancreatic cancer can be determined by a doctor based on the UICC TNM classification (UICC: TNM Classification of Malignant Tumors, 8th Edn. Willey-Blackwell; 2017.94-95).
  • Stage I includes stages 1A and 1B
  • stage II includes stages 2A and 2B.
  • Stages III and IV are synonymous with stages 3 and 4, respectively.
  • Information can be provided by sending or outputting information.
  • the output of information can be on a display or printed matter.
  • the analytical method of the present invention may further include determining that the subject has the potential to have cancer.
  • cancer therapies include one or more selected from the group consisting of radiation therapy, chemotherapy, and surgical therapies.
  • Cancer therapy can be standard therapy.
  • Radiation therapy may include irradiating the cancer with radiation.
  • Chemotherapy may include administering an anticancer drug to a subject.
  • Surgical treatment may include removing the cancer.
  • Chemotherapy for cancer includes, for example, forfilinox therapy, gemcitabine / nabpaclitaxel therapy (GnP therapy), gemcitabine / S1 therapy (GS therapy), liposomal irinotecan / 5FU / LV therapy. (Nal-IRI / FL therapy), gemcitabine therapy, S1 therapy and the like, and the subject can be treated by any one or more of these therapies.
  • the anticancer agent is selected from the group consisting of, for example, platinum preparations such as oxaliplatin, irinotecan, liposome-type irinotecan, levofolinate, gemcitabine, nab-paclitaxel, 5-fluorouracil (5-FU), and S-1.
  • platinum preparations such as oxaliplatin, irinotecan, liposome-type irinotecan, levofolinate, gemcitabine, nab-paclitaxel, 5-fluorouracil (5-FU), and S-1.
  • platinum preparations such as oxaliplatin, irinotecan, liposome-type irinotecan, levofolinate, gemcitabine, nab-paclitaxel, 5-fluorouracil (5-FU), and S-1.
  • oxaliplatin irinotecan, liposome-type irinotecan, levofolinate, gemcitabine,
  • a method of analyzing the inside of a biological sample obtained from a subject.
  • a biological sample by a sandwich assay or immunochromatography assay performed using a first molecule selected from the group consisting of an antibody that binds to BC2LCN, SerpinA3, and an antibody that binds to Gal3BP, and a second molecule that is BC2LCN.
  • Methods are provided that include analyzing components (eg, blood components) contained in (eg, blood samples).
  • the first molecule is immobilized on a support (eg, substrate) and the second molecule can be labeled. In some embodiments, the first molecule can be labeled and the second molecule can be immobilized on the support.
  • Immobilization can be performed by, for example, a direct method, a polystyrene tag method (WO2018 / 190357), a biotin-streptavidin method, a HaloTag method, a method using a chemical bond such as an amine coupling method, and a known solidification such as a V5 tag method.
  • a phase conversion method can be used.
  • the direct method the captive molecule to be immobilized is directly contacted with the support, thereby immobilizing on the support.
  • the polystyrene tag method the polystyrene plate is immobilized on the polystyrene plate via the polystyrene tag fused to the trapping molecule.
  • the capture molecule is immobilized on the support by binding the capture molecule modified with biotin to the support coated with streptavidin.
  • the capture molecule is immobilized on the support coated with HaloTag via the HaloTag protein fused to the capture molecule.
  • the amine coupling method a carboxyl group formed on the surface of a solid phase can be activated esterified, and a protein or the like can be immobilized by a chemical bond via an amino group.
  • the capture molecule is immobilized on the support by binding the capture molecule to which the V5 tag is linked to the support coated with the anti-V5 tag antibody.
  • substrates color-developing substrate, fluorescent substrate, and luminescent substrate
  • enzymes used in the enzyme antibody method for example, peroxidase, glucose oxidase, and alkaline phosphatase
  • Labeling can be performed by those skilled in the art using a conventional method. Labeling can be done, for example, in a covalent bond. Labeling may be performed by reacting, for example, a biotin-linked antibody with an avidin-linked label. Examples of the substrate include a fluorescent substrate.
  • the peroxidase for example, horseradish peroxidase can be used.
  • Horseradish peroxidase produces color, fluorescence or chemiluminescence by adding a chromogenic, fluorescent or chemiluminescent substrate. Therefore, the presence of a trapped molecule labeled with color development, fluorescence or chemiluminescence as an index can be detected.
  • Coloring substrates for horseradish peroxidase include, for example, tetramethylbenzidine (TMB), o-phenylenediamine (OPD), 2,2-azinobis [3-ethylbenzo-thiazolin-6-sulfonic acid (ABTS), and Amplex ( Trademark) Red can be used to detect labeled molecules in the presence of hydrogen peroxide.
  • Luminescent substrates for alkaline phosphatase include p-nitrophenyl phosphate (pNPP), 4-methylumbelliferyl phosphate (4-MUP), and AttoPhos TM, which can be used to detect trapping molecules.
  • pNPP p-nitrophenyl phosphate
  • 4-MUP 4-methylumbelliferyl phosphate
  • AttoPhos TM which can be used to detect trapping molecules.
  • Glucose oxidase oxidizes glucose to generate gluconic acid and hydrogen peroxide.
  • Hydrogen peroxide can be easily detected using, for example, a colorimetric probe for detecting hydrogen peroxide (for example, peroxidase). Hydrogen peroxide can develop color, for example, in the presence of peroxidase and its chromogenic substrate.
  • a dye for example, a colorant, for example, colloidal gold
  • a colorant for example, colloidal gold
  • the first molecule is BC2LCN.
  • recombinant BC2LCN can be used as BC2LCN.
  • BC2LCN may be directly immobilized or, for example, immobilized on a streptavidin (or neutralvidin) -coated support that is biotin-labeled.
  • BC2LCN may be fused with the HaloTag protein and then immobilized on a support coated with the HaloTag ligand.
  • BC2LCN may be fused with a polystyrene tag and then directly immobilized on a polystyrene plate.
  • the target component detected by the sandwich assay and the immunochromatographic assay in which the first molecule is BC2LCN is a component that can bind to a plurality of BC2LCNs at the same time.
  • an antibody against BC2LCN and a sugar chain antigen that binds to BC2LCN such as H-type1 sugar chain antigen and H-type3 sugar chain antigen can be immobilized on the control line.
  • the first molecule is an antibody that binds to Serpin A3.
  • Serpin A3 having a BC2LCN-binding sugar chain has been detected.
  • the antibody that binds to Serpin A3 can be prepared by a conventional method using the binding property to Serpin A3 as an index.
  • the antibody that binds to SerpinA3 may be further confirmed by having binding to SerpinA3 having a BC2LCN-binding sugar chain.
  • Serpin A3 having a BC2LCN-binding sugar chain can be purified as a component that reacts with the immobilized BC2LCN and the antibody that binds to Serpin A3, as used in the examples.
  • the antibody that binds to Serpin A3 may be selected based on whether or not it binds to the purified component.
  • the first molecule is an antibody that binds to Serpin A3
  • the first molecule is immobilized on a support (eg, substrate or beads) and the second molecule can be labeled; or the first.
  • the molecule is labeled and the second molecule can be immobilized on the support.
  • the first molecule is an antibody that binds to Gal3BP.
  • Gal3BP having a BC2LCN-binding sugar chain has been detected.
  • the antibody that binds to Gal3BP can be prepared by a conventional method using the binding property to Gal3BP as an index.
  • the antibody that binds to Gal3BP may be further confirmed by having binding to Gal3BP having a BC2LCN-binding sugar chain.
  • Gal3BP having a BC2LCN-binding sugar chain can be purified as a component that reacts with the immobilized BC2LCN and an antibody that binds to Gal3BP, as used in the examples.
  • the antibody that binds to Gal3BP may be selected using whether or not it binds to the purified component as an index.
  • the first molecule is an antibody that binds to Gal3BP
  • the first molecule can be immobilized on a support (eg, substrate or beads) and the second molecule can be labeled; or the first.
  • the molecule is labeled and the second molecule can be immobilized on the support.
  • a method of predicting whether or not a subject has cancer a method of obtaining preliminary information on whether or not the subject has cancer, a method of determining whether or not the subject has cancer, and a method of determining whether or not the subject has cancer.
  • a method or preliminary method for predicting whether or not cancer is present, a method for detecting cancer in a subject, a method for detecting cancer cells in a subject, a method for detecting a biomarker for cancer in a subject (biomarker).
  • biomarker Is a component selected from the group consisting of a component capable of simultaneously binding two BC2LCNs, a BC2LCN-binding SerpinA3, and a BC2LCN-binding Gal3BP), or whether or not the subject has cancer.
  • the method is Including analyzing the presence or concentration of a component (eg, a blood component) in a biological sample (eg, a blood sample), the component (eg, a blood component) is a component capable of simultaneously binding two BC2LCNs, BC2LCN.
  • a component selected from the group consisting of binding Serpin A3 and BC2LCN binding Gal3BP; or with a first molecule selected from the group consisting of BC2LCN, an antibody that binds Serpin A3, and an antibody that binds Gal3BP.
  • a method for detecting a component (for example, a blood component) in a target biological sample for example, a blood sample
  • the component for example, a blood component
  • a method is provided which is a component selected from the group consisting of possible components, BC2LCN-binding Serpin A3, and BC2LCN-binding Gal3BP.
  • a first molecule selected from the group consisting of an antibody that binds to BC2LCN, SerpinA3, and an antibody that binds to Gal3BP and a second molecule that is BC2LCN are contacted with a biological sample (for example, a blood sample).
  • This method is a sandwich assay or immunochromatography assay performed using a first molecule selected from the group consisting of an antibody that binds to BC2LCN, SerpinA3, and an antibody that binds to Gal3BP, and a second molecule that is BC2LCN.
  • a first molecule selected from the group consisting of an antibody that binds to BC2LCN, an antibody that binds to Serpin A3, and an antibody that binds to Gal3BP, and a second molecule that is BC2LCN are included, and the first molecule and the first molecule.
  • Kits for sandwich assays or immunochromatographic assays are provided that can measure the amount of glycoprotein in a biological sample of interest (eg, a blood sample) using two molecules.
  • the first molecule is immobilized on a substrate or strip and the second molecule is labeled.
  • the first molecule is labeled and the second molecule is immobilized on a substrate or strip.
  • the first molecule is labeled and the second molecule is contained in or immobilized on the gel.
  • the kit of the present invention may further contain a chromogenic substrate when the label is an enzyme used in an enzyme antibody method. If the biological sample is a blood sample, the component is a blood component.
  • the first molecule is BC2LCN. In some aspects of the invention, the first molecule is an antibody that binds to Serpin A3. In some aspects of the invention, the first molecule is an antibody that binds to Gal3BP.
  • the kit of the present invention can be used for detection of a target molecule, or for detection, determination, prediction, or diagnosis of cancer.
  • a combination of a first molecule selected from the group consisting of an antibody that binds to BC2LCN, SerpinA3, and an antibody that binds to Gal3BP and a second molecule that is BC2LCN is provided.
  • a component selected from the group consisting of a component capable of simultaneously binding two BC2LCNs, a BC2LCN-binding SerpinA3, and a BC2LCN-binding Gal3BP is sampled (for example, a biological sample or a biological sample (for example, a biological sample or a biological sample (for example). For example, it can be used for detection in blood samples)).
  • one of the first molecule and the second molecule may be immobilized on the support and the other may be labeled for detection.
  • the above combination can be used to diagnose cancer using a biological sample (eg, a blood sample).
  • a kit including the above combination used for diagnosing cancer using a biological sample is provided.
  • the combination may be a kit for a sandwich assay, a kit for an immunochromatography assay, a kit for lectin electrophoresis, a kit for mass spectrometry, a kit for lectin affinity chromatography or a kit for ⁇ TAS.
  • Kits for lectin electrophoresis can include gels containing lectins.
  • Kits for lectin affinity chromatography can include a column containing a support on which the lectin is immobilized. These kits may further include purified Serpin A3, purified BC2LCN binding Serpin A3, purified Gal3BP, purified BC2LCN binding Gal3BP, and the like as reference materials.
  • the kit for ⁇ TAS may include a microfluidic chip.
  • the microfluidic chip has a detection unit, and the detection unit includes one or more selected from the group consisting of SerpinA3, BC2LCN-binding SerpinA3, Gal3BP, and BC2LCN-binding Gal3BP, and a protein complex containing these.
  • the molecule to be bound can be immobilized.
  • a method for analyzing a biological sample obtained from a subject in the present invention is carried out using a first molecule selected from the group consisting of a molecule that binds to a BC2LCN-binding sugar chain, a molecule that binds to SerpinA3, and a molecule that binds to Gal3BP, and a second molecule that is BC2LCN.
  • the signal obtained by the assay reduces cancer in the body (eg, cancer). Can be reduced by removal). Therefore, in the methods of the invention, the assay signal can indicate the amount of cancer in the body.
  • the signal obtained by the assay can be increased by recurrence. Therefore, in the method of the invention, an increased signal may indicate a recurrence of the cancer.
  • a method comprising separating from a biological sample obtained from a subject one or more components selected from the group consisting of two BC2LCNs capable of binding simultaneously, Serpin A3 and Gal3BP. ..
  • the present invention also provides a method comprising detecting from a biological sample obtained from a subject one or more components selected from the group consisting of two BC2LCNs capable of binding simultaneously, Serpin A3 and Gal3BP.
  • a method of analyzing a biological sample obtained from a subject Containing the separation of one or more components selected from the group consisting of Serpin A3 and Gal3BP, components capable of simultaneously binding to two BC2LCNs in a biological sample obtained from the subject. The method is provided.
  • Separation means separating the target component from at least one or more of the other components. Separation can include enrichment, enrichment, and purification of the component of interest. Concentration means increasing the concentration. Enrichment and purification means selectively increasing the abundance ratio of the desired component to other components. Enrichment and purification may involve enrichment of the components of interest. Separation can also include binding to immobilized molecules. In this case, by binding to the immobilized molecule, it is separated from other components that do not bind. Separation may include removing non-adsorbed components in addition to adsorbing the components of interest on the immobilized surface. The non-adsorbed components can be removed by cleaning the surface.
  • Removal of non-adsorbed components can also be performed by removal of the liquid phase. Removal of the non-adsorbed component may also be performed by recovering the beads if a solid phase is present on the surface of the beads.
  • the invention may further comprise measuring the amount of separated components. Measurements can be performed by assays well known to those of skill in the art, which can give assay signals. The measured amount can be compared with other indicators (eg, cutoff values). The cutoff value can be as described above.
  • the method of the present invention when the measured amount is larger than the other amount as an index, it can be indicated that the target from which the biological sample is derived may be cancer. Therefore, the method of the present invention is a method for detecting cancer, a method for detecting cancer cells, a method for diagnosing cancer, a non-diagnostic method for diagnosing cancer, and a method for diagnosing cancer. It can be a method of obtaining preliminary information for predicting cancer, a method of predicting cancer, or a non-diagnostic method for predicting cancer.
  • the signal obtained by the assay can be reduced by reducing the cancer in the body (eg, removing the cancer). Therefore, in the methods of the invention, the assay signal can indicate the amount of cancer in the body.
  • the signal obtained by the assay can be increased by recurrence. Therefore, in the method of the invention, an increased signal may indicate a recurrence of the cancer.
  • the method of the present invention can be performed on two or more biological samples collected at different time points.
  • the biological sample can be two or more biological samples recovered at different time points.
  • the method of the invention further comprises comparing the signal obtained by the assay (corresponding to the measured amount) with the signal obtained in another sample that could be recovered at that different time point. You may. In this way, the present invention can be used to monitor a patient's cancer treatment process and / or recurrence process.
  • the method of the present invention may be carried out in combination with an existing method.
  • an existing method a method including measuring the amount of CA19-9 in a body fluid sample is known.
  • CA19-9 is increasing in concentration in body fluid samples with cancer. Also, as the amount of cancer increases, its concentration increases, and as the amount of cancer decreases, its concentration decreases.
  • the combination of CA19-9 and the method of the invention can enhance the accuracy and / or specificity of cancer detection by analysis of body fluid samples.
  • CA19-9 can be an indicator of pancreatic cancer, especially pancreatic cancer such as stage III and IV. Therefore, the present invention may further include measuring the concentration of CA19-9 in a biological sample.
  • One or more components selected from the group consisting of Serpin A3 and Gal3BP to be measured may be further analyzed using BC2LCN-binding sugar chain modification as an index. Whether or not one or more components selected from the group consisting of Serpin A3 and Gal3BP has a BC2LCN-binding sugar chain modification is determined by using a factor that binds to the sugar modification (sugar chain) as described above. can do. Alternatively, one or more components selected from the group consisting of Serpin A3 and Gal3BP may be detected after separation using a factor that binds to the sugar modification (sugar chain). One or more components selected from the group consisting of Serpin A3 and Gal3BP may be detected after separation using a molecule that binds to Serpin A3 and a molecule that binds to Gal3BP.
  • Example 1 Detection of Glycoprotein in Serum of Cancer Patients Using rBC2LCN Glycoprotein in serum of patients with various cancers was detected by a sandwich assay using rBC2LCN.
  • biotinylated rBC2LCN was diluted with PBS to 0.3 ⁇ g / mL, added to an avidin plate (blockingless type) (Sumitomo Bakelite, BS-X7603) at 50 ⁇ L / well, and incubated at room temperature for 1 hour.
  • the glycoproteins detected by the sandwich assay with rBC2LCN are pancreatic cancer patients, colon cancer patients, bladder cancer patients, breast cancer patients, non-Hodgkin's lymphoma patients, uterine body cancer patients, and ovarian cancer. It was revealed that the concentration was higher than the maximum value observed in the healthy group in cancer patients and patients with chronic myelogenous leukemia.
  • the detected glycoprotein must be able to bind at the same time as two molecules, the immobilized rBC2LCN and the detection rBC2LCN.
  • the components that can bind simultaneously with the two molecules of rBC2LCN eg, blood components
  • the components eg, blood. It became clear that it is useful for the analysis of components).
  • Example 2 Identification of glycoprotein recognized by rBC2LCN
  • glycoproteins in the sera of pancreatic cancer patients and healthy subjects were precipitated with rBC2LCN-binding beads, and the precipitated glycoproteins were eluted with rBC2LCN.
  • the obtained eluate was electrophoresed, and glycoproteins specific to pancreatic cancer were identified by mass analysis.
  • Biotinylated rBC2LCN was bound to Dynabeads M280 Streptavidin (Invitrogen). Then, the glycoprotein bound to rBC2LCN was eluted by incubating with pancreatic cancer and healthy person's serum overnight at 4 ° C., washing, adding 0.2 M fucose, and incubating at room temperature for 1 hour. The obtained eluate was electrophoresed, transferred to a PVDF membrane, and then blotted with HRP-labeled rBC2LCN. As a result, although no reactivity was observed in the rBC2LCN blot in the serum of healthy subjects, the reactivity was observed in the vicinity of 75-150 kDa in the pancreatic cancer serum.
  • glycoprotein showing binding to rBC2LCN-immobilized beads was electrophoresed from pancreatic cancer and healthy person's serum, and Western blot was performed using an antibody against Serpin A3, an antibody against Gal3BP, and an HRP-labeled secondary antibody.
  • SerpinA3 and Gal3BP were detected significantly more strongly in the sera of pancreatic cancer patients than in healthy subjects.
  • Serpin A3 and Gal3BP were obtained as proteins adsorbed on beads by rBC2LCN, and therefore these glycoproteins were found to be reactive to rBC2LCN.
  • biotinylated anti-mouse IgG manufactured by Nichirei Bioscience, product number: 424021, dilution ratio: stock solution
  • biotinylated anti-goat IgG manufactured by Nichirei Bioscience, product number: 414011, respectively.
  • Dilution ratio undiluted solution
  • Serpin A3 and Gal3BP detected in blood are derived from the pancreatic duct of pancreatic cancer tissue.
  • Example 3 Analysis of sera of cancer patients in a sandwich assay using rBC2LCN and SerpinA3 antibody or Gal3BP antibody Therefore, a sandwich assay of rBC2LCN and SerpinA3 antibody was constructed in healthy subjects and various cancers including pancreatic cancer. The patient's serum was analyzed. Biotinylated rBC2LCN was diluted with PBS to 0.3 ⁇ g / mL, added to an avidin plate (blockingless type) (Sumitomo Bakelite, BS-X7603) at 50 ⁇ L / well, and incubated at room temperature for 1 hour.
  • an avidin plate blockingless type
  • the glycoprotein detected by the sandwich assay of rBC2LCN and SerpinA3 antibody can hardly be detected in healthy subjects.
  • colon cancer, pancreatic cancer, bladder cancer, gastric cancer, small cell lung cancer, breast cancer, non-hodgkin lymphoma, cervical cancer, rectal adenocarcinoma, stem cell cancer, thyroid cancer, prostate cancer was strongly detected in all of uterine body cancer, melanoma, esophageal cancer, ovarian cancer, bile duct cancer, and chronic myeloid leukemia (all of the cancers examined).
  • rBC2LCN and Gal3BP antibody were constructed, and sera of healthy subjects and various cancer patients including pancreatic cancer were analyzed.
  • Biotinylated rBC2LCN was diluted with PBS to 0.3 ⁇ g / mL, added to an avidin plate (blockingless type) (Sumitomo Bakelite, BS-X7603) at 50 ⁇ L / well, and incubated at room temperature for 1 hour.
  • the glycoprotein detected by the sandwich assay of rBC2LCN and Gal3BP antibody (that is, Gal3BP having a specific sugar chain that binds to BC2LCN lectin) can hardly be detected in healthy subjects.
  • colon cancer, pancreatic cancer, bladder cancer, gastric cancer, small cell lung cancer, breast cancer, non-hodgkin lymphoma, cervical cancer, rectal adenocarcinoma, stem cell cancer, thyroid cancer, prostate cancer was strongly detected in all of uterine body cancer, melanoma, esophageal cancer, ovarian cancer, bile duct cancer, and chronic myeloid leukemia (all of the cancers examined).
  • FIG. 10 a comparison was made by dividing into healthy subjects, pancreatitis patients, and pancreatic cancer patients.
  • the sandwich assay of rBC2LCN and rBC2LCN the sandwich assay of rBC2LCN and anti-SerpinA3 antibody
  • the sandwich assay of rBC2LCN and anti-Gal3BP antibody the sandwich assay of anti-SerpinA3 antibody and anti-SerpinA3 antibody
  • stronger signals were detected in patients and patients with pancreatitis. This suggests that these assays can distinguish pancreatic cancer patients from healthy individuals and pancreatitis patients.
  • a sandwich assay with rBC2LCN and rBC2LCN using serum specimens from other healthy individuals and serum specimens from pancreatic cancer patients, a sandwich assay with rBC2LCN and rBC2LCN, a sandwich assay with rBC2LCN and anti-Serpin A3 antibody, rBC2LCN and anti-virus, as described above.
  • a sandwich assay with Gal3BP antibody and a sandwich assay with anti-Serum A3 antibody (R & D Systems, Cat #: AF1295) and anti-Serum A3 antibody were performed.
  • the ROC curved point at the shortest distance from the specificity 1) was 0.01, the specificity at that time was 0.900, and the sensitivity was 0.575. Further, as shown in the lower right panel of FIG. 7, in the sandwich assay (SerpinA3-SerpinA3) using the anti-Serpin A3 antibody and the anti-Serpin A3 antibody, the area under the ROC curve (AUC) was 0.718, and the cut in the ROC curve was obtained.
  • Off sensitivity 1, determined from the ROC curved point at the shortest distance from specificity 1) was 1.056, the specificity at that time was 0.8, and the sensitivity was 0.65. ..
  • the sandwich assay with rBC2LCN and anti-SerpinA3 antibody has the best accuracy, and the sandwich assay with rBC2LCN and anti-Gal3BP antibody (rBC2-Gal3BP) shows the best specificity. It became clear. In addition, it was revealed that the sandwich assay using rBC2LCN and rBC2LCN (rBC2-rBC2) and the sandwich assay using anti-SerpinA3 antibody and anti-SerpinA3 antibody (SerpinA3-SerpinA3) also show accuracy having a certain degree of usefulness.
  • Example 5 Analysis of Serum of Patients with Pancreatic Cancer by Stage
  • serum samples of patients with various pancreatic cancers from stage 1A to stage 4 were evaluated by a sandwich assay.
  • the stage of cancer was determined by the doctor based on the UICC TNM classification (UICC: TNM Classification of Malignant Tumors, 8th Edn. Wiley-Blackwell; 2017.94-95).
  • Serum of cancer patients as described in Examples 1 and 3 sandwich assay with rBC2LCN and rBC2LCN, sandwich assay with rBC2LCN and anti-SerpinA3 antibody, sandwich assay with rBC2LCN and anti-Gal3BP antibody, and anti-SerpinA3 antibody and anti-SerpinA3 antibody.
  • sandwich assay according to. The results were as shown in FIGS. 8A-8D.
  • the sandwich assay with rBC2LCN and rBC2LCN, the sandwich assay with rBC2LCN and anti-Serpin A3 antibody, and the sandwich assay with rBC2LCN and anti-Gal3BP antibody had high measurements at all stages 1 through 4. Samples showing strength were found.
  • the sandwich assay with anti-Serpin A3 and anti-Serpin A3 antibodies showed high measurement intensities in all samples, similar to that shown in FIG.
  • stage I pancreatic cancer patients were successfully detected in any of the sandwich assays.
  • Pancreatic cancer was removed from patients with pancreatic cancer.
  • the results of the sandwich assay of rBC2LCN and anti-Serpin A3 antibody are shown in FIG. 16, the results of the sandwich assay of rBC2LCN and anti-Gal3BP antibody are shown in FIG. 17, and the results of the CA19-9 assay are shown in FIG.
  • 30 POD means 30 days after surgery and 3 m means 3 months after surgery.
  • the signal for each sandwich assay was reduced by cancer resection. Therefore, in these assays, it can be seen that the outcome of cancer removal affects the content of components in the blood.
  • the assay was a sandwich assay using BC2LCN and anti-Serpin A3 antibody.
  • the results were as shown in FIG. As shown in FIG. 19, in patient A, the assay signal decreased over time after surgery. However, analysis of the blood of patient A who had relapsed showed a marked increase in signal. This suggests that the assay system of the present invention can be used to detect recurrence.
  • pancreatic cancer such as stages 1 and 2 can be obtained by appropriately setting the cutoff value. It can detect a wide range of cancers from stage 4 pancreatic cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
PCT/JP2020/038300 2019-10-11 2020-10-09 がんの検査方法 Ceased WO2021070934A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP20873535.7A EP4043881A4 (en) 2019-10-11 2020-10-09 CANCER TEST PROCEDURE
KR1020227012018A KR102896955B1 (ko) 2019-10-11 2020-10-09 암의 검사 방법
CN202080071169.XA CN114556101B (zh) 2019-10-11 2020-10-09 癌的检查方法
JP2021551720A JP7656829B2 (ja) 2019-10-11 2020-10-09 がんの検査方法
US17/717,764 US12618842B2 (en) 2019-10-11 2022-04-11 Cancer test method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-187197 2019-10-11
JP2019187197 2019-10-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/717,764 Continuation US12618842B2 (en) 2019-10-11 2022-04-11 Cancer test method

Publications (1)

Publication Number Publication Date
WO2021070934A1 true WO2021070934A1 (ja) 2021-04-15

Family

ID=75438180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/038300 Ceased WO2021070934A1 (ja) 2019-10-11 2020-10-09 がんの検査方法

Country Status (6)

Country Link
US (1) US12618842B2 (cg-RX-API-DMAC7.html)
EP (1) EP4043881A4 (cg-RX-API-DMAC7.html)
JP (1) JP7656829B2 (cg-RX-API-DMAC7.html)
KR (1) KR102896955B1 (cg-RX-API-DMAC7.html)
CN (1) CN114556101B (cg-RX-API-DMAC7.html)
WO (1) WO2021070934A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022183145A (ja) * 2021-05-28 2022-12-08 独立行政法人国立病院機構 抗原固相化デバイス
WO2025187809A1 (ja) * 2024-03-08 2025-09-12 富士フイルム株式会社 検出対象物質を免疫学的に検出する方法、非特異反応を抑制する方法、フコース含有組成物、および試薬キット

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012173002A1 (ja) 2011-06-15 2012-12-20 三洋化成工業株式会社 磁性シリカ粒子を用いた測定方法及び該測定方法用試薬
WO2014126146A1 (ja) 2013-02-14 2014-08-21 独立行政法人産業技術総合研究所 未分化細胞除去方法
WO2017061449A1 (ja) 2015-10-05 2017-04-13 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物
WO2018190357A1 (ja) 2017-04-11 2018-10-18 国立研究開発法人産業技術総合研究所 レクチンの固定化方法
JP2020146027A (ja) 2018-08-13 2020-09-17 東ソー株式会社 糖鎖への親和性が向上したフコース結合性タンパク質、およびその製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
WO2013172105A1 (ja) * 2012-05-18 2013-11-21 日東紡績株式会社 膵臓癌を検出するためのマーカー

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012173002A1 (ja) 2011-06-15 2012-12-20 三洋化成工業株式会社 磁性シリカ粒子を用いた測定方法及び該測定方法用試薬
WO2014126146A1 (ja) 2013-02-14 2014-08-21 独立行政法人産業技術総合研究所 未分化細胞除去方法
WO2017061449A1 (ja) 2015-10-05 2017-04-13 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物
WO2018190357A1 (ja) 2017-04-11 2018-10-18 国立研究開発法人産業技術総合研究所 レクチンの固定化方法
JP2020146027A (ja) 2018-08-13 2020-09-17 東ソー株式会社 糖鎖への親和性が向上したフコース結合性タンパク質、およびその製造方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"UICC: TNM Classification of Malignant Tumors", 2017, WILEY-BLACKWELL, pages: 94 - 95
KIMYO, TAKUMA ET AL.: "Development of new clinical markers using serum glycoproteins-linked sugar chains", THE OFFICIAL JOURNAL OF JAPANESE SOCIETY OF LABORATORY MEDICINE, vol. 62, no. Suppl., 30 November 2013 (2013-11-30), JP , pages 140, XP009535380, ISSN: 0047-1860 *
KOTHS, K. ET AL., J. BIOL. CHEM., vol. 268, 1993, pages 14245 - 14249
KOTHS, K. ET AL.: "Cloning and characterization of a human Mac-2-bincling protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain", J. BIOL. CHEM., vol. 268, no. 19, 1993, pages 14245 - 14249, XP002914299, ISSN: 0021-9258 *
NIE, S. ET AL., J. PROTEOME RES., vol. 13, 2014, pages 1873 - 1884
See also references of EP4043881A4
SULAK, O. ET AL., STRUCTURE, vol. 18, no. 1, 2010, pages 59 - 72

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022183145A (ja) * 2021-05-28 2022-12-08 独立行政法人国立病院機構 抗原固相化デバイス
JP2022182394A (ja) * 2021-05-28 2022-12-08 独立行政法人国立病院機構 抗原固相化デバイス
JP7421183B2 (ja) 2021-05-28 2024-01-24 独立行政法人国立病院機構 抗原固相化デバイス
WO2025187809A1 (ja) * 2024-03-08 2025-09-12 富士フイルム株式会社 検出対象物質を免疫学的に検出する方法、非特異反応を抑制する方法、フコース含有組成物、および試薬キット

Also Published As

Publication number Publication date
KR20220079855A (ko) 2022-06-14
JP7656829B2 (ja) 2025-04-04
EP4043881A1 (en) 2022-08-17
EP4043881A4 (en) 2022-11-23
US12618842B2 (en) 2026-05-05
KR102896955B1 (ko) 2025-12-05
US20220236275A1 (en) 2022-07-28
CN114556101A (zh) 2022-05-27
JPWO2021070934A1 (cg-RX-API-DMAC7.html) 2021-04-15
CN114556101B (zh) 2025-09-26

Similar Documents

Publication Publication Date Title
JP5787389B2 (ja) 肝内胆管がんの検出、判別方法
EP1137943B1 (en) Cancer detection method and reagents
WO2022063156A1 (zh) 乳腺癌的生物标志物及其应用
JP7042815B2 (ja) レクチンベースの癌の診断
JP2012506253A (ja) 大腸癌関連マーカーを用いた大腸癌の診断キット、及びそれを用いた大腸癌の診断方法
WO2022083673A1 (zh) 食管癌的生物标志物及其应用
CN111065925B (zh) Agrin在诊断子宫内膜癌中的应用
WO2022083603A1 (zh) 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用
WO2016195051A1 (ja) 膵がんを診断するための血漿バイオマーカーパネル
US20030138860A1 (en) Cancer detection methods and reagents
US12618842B2 (en) Cancer test method
EP3796001B1 (en) Method for determining prostate carcinoma
CN120334544B (zh) 鼻咽癌抗体标志物及其应用
KR101144324B1 (ko) 대장암 예후진단용 단백질 마커 디펜신?5와 rod1단백질의 조합 및 이들 각각에 대한 항체를 포함하는 대장암 예후진단키트
JP7709703B2 (ja) 膵臓がんの検出方法及び検出試薬
CA3255282A1 (en) METHODS AND SYSTEMS FOR RISK STRATIFICATION AND BLADDER CANCER MANAGEMENT
JP5221825B1 (ja) 肺扁平上皮癌の検出方法
WO2020240011A1 (en) Method for diagnosing colorectal cancer
KR20240068432A (ko) 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트
EP4505174A1 (en) Biomarkers for the determination of sample adequacy and lung cancer metastases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20873535

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021551720

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020873535

Country of ref document: EP

Effective date: 20220511